Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
5.70
0.00 (0.00%)
Aug 29, 2025, 4:00 PM - Market closed
Radiopharm Theranostics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Radiopharm Theranostics stock have a consensus rating of "Strong Buy" and an average price target of $15, which forecasts a 163.16% increase in the stock price over the next year. The lowest target is $12 and the highest is $18.
Price Target: $15 (+163.16%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 21, 2025.
Analyst Ratings
The average analyst rating for Radiopharm Theranostics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +215.79% | Jul 21, 2025 |
| Maxim Group | Maxim Group | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +110.53% | May 1, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +163.16% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
4.58M
from 1.96M
Increased by 133.95%
Revenue Next Year
45.25M
from 4.58M
Increased by 887.52%
EPS This Year
-0.02
from -0.12
EPS Next Year
-0.02
from -0.02
Financial currency is AUD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.8M | 47.0M | ||||
| Avg | 4.6M | 45.2M | ||||
| Low | 4.4M | 43.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 143.2% | 926.6% | ||||
| Avg | 134.0% | 887.5% | ||||
| Low | 127.0% | 858.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.02 | -0.01 | ||||
| Avg | -0.02 | -0.02 | ||||
| Low | -0.02 | -0.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.